Sixty-six Salmonella enterica serovar Typhimurium isolates carrying incompatibility group FIB (IncFIB) plasmids were sequenced to further characterize the IncFIB plasmid-encoded factors associated with virulence and antimicrobial resistance genes. In addition to the IncFIB plasmid, many of these isolates harbored additional plasmids encoding virulence and antimicrobial resistance genes.
S almonella enterica, a major foodborne pathogen, has been identified as the source of multiple outbreaks linked to contaminated foods or pet animals in the United States (1, 2) . Among 2,600 Salmonella serovars identified, Typhimurium is one of the predominant serovars that can cause illness in animals and humans (3, 4) . S. enterica contains arrays of virulence factors commonly encoded on Salmonella pathogenicity islands (SPIs) located on the chromosome (3, 4) . Additionally, some plasmids, including incompatibility group FIB (IncFIB) plasmids, are known to encode virulence factors and antimicrobial resistance phenotypes (5, 6) . However, much remains to be studied regarding plasmid factors that give bacteria enhanced capacity to compete in food animal environments and cause human infections. The aim of this study was to evaluate the antimicrobial resistance and virulence gene content of a historical collection of IncFIB-positive S. enterica serovar Typhimurium isolates. Sixty-six S. enterica serovar Typhimurium isolates originating from chickens (n ϭ 32, 48%), turkeys (n ϭ 18, 27%), cattle (n ϭ 10, 15%), swine (n ϭ 4, 6%), and poultry water (n ϭ 2, 3%) were sequenced. These isolates were collected from different locations in the United States in 1999 and 2003.
S. Typhimurium isolates were identified and phenotypically characterized using standard microbiological methods (4). Sixty-six S. Typhimurium isolates identified as carrying the IncFIB plasmid using PCR-based plasmid replicon typing were sequenced (7) . Each isolate was stored at -80°C in brain heart infusion broth (Remel, Lenexa, KS) containing 20% glycerol and subsequently subcultured on blood agar plates (tryptic soy agar with 5% sheep's blood [Remel] ) and incubated at 35°C for 24 hours. After overnight incubation, bacterial growth was collected from the plate using a 1-l inoculating loop and added to 180 l animal tissue lysis (ATL) buffer (Qiagen, Valencia, CA, USA) (8) . The bacterial genomic DNA was extracted using a DNeasy blood and tissue kit (Qiagen). A Nanodrop instrument and a Qubit broad-range (BR) assay kit were used to measure the quality and quantity of the DNA (Thermo Fisher Scientific, Grand Island, NY, USA). DNA sequencing libraries were constructed with the Nextera XT DNA library preparation kit (Illumina, San Diego, CA), and samples were multiplexed with a combination of two indexes of the Nextera XT index kit. Whole-genome sequencing (WGS) reactions were performed on an Illumina MiSeq instrument with a 2 ϫ 250-bp pairedend format (8) .
The raw sequence data were trimmed, and de novo assembly was completed using CLC Genomics Workbench version 9.0 (Qiagen, Redwood City, CA). Sequences were annotated initially using the Pathosystems Resource Integration Center (PATRIC) software version 3.5.36 (9) and then submitted to NCBI for final annotation with the Prokaryotic Genome Annotation Pipeline (PGAP) (10) . The number of contigs, genome length (bp), coding sequences (CDSs), and GϩC content of each sample were annotated via PATRIC as listed in Table 1 . The final annotations performed using PGAP are available at NCBI under the accession numbers shown in Table 1 . The WGS results were further analyzed using PlasmidFinder (11) , ResFinder (12) , and the PATRIC_VF database (9) to characterize and identify the antimicrobial resistance and putative virulence genes carried by the IncFIB plasmids. Each of the analyses was performed using default parameter settings. PlasmidFinder analyses showed that all of the isolates contained IncFIB plasmids along with other plasmid replicon types, including IncColpVC (n ϭ 43, 65%), IncFIC(FII) (n ϭ 34, 52%), IncI1 (n ϭ 30, 45%), IncFIA (n ϭ 19, 29%), IncA/C2 (n ϭ 16, 24%), IncFII(pcoo) (n ϭ 15, 23%), InFII(S) (n ϭ 14, 21%), IncX1 (n ϭ 11, 17%), IncHI2A (n ϭ 8, 12%), and IncHI2 (n ϭ 7, 11%). Multiple antimicrobial resistance genes, including bla CMY-2 in 65% (n ϭ 43) of the total isolates, followed by tet(A) (n ϭ 27, 40%), tet(B) (n ϭ 24, 36%), bla TEM-1B (n ϭ 22, 33%), sul2 (n ϭ 19, 29%), sul1 (n ϭ 17, 26%), tet(G) (n ϭ 2, 3%), and bla TEM (n ϭ 1, 1.5%), were identified. WGS analysis using PATRIC identified several virulence genes, including iron acquisition genes, such as iroN (n ϭ 66, 100%), iutA (n ϭ 65, 98%), sitA (n ϭ 65, 98%), and iucA (n ϭ 49, 74%). Additionally, all isolates contained chromosomally encoded Salmonella pathogenicity island 1 (SPI-1) and SPI-2 genes. WGS-based sequence analyses facilitate a better understanding of the genetics of the antimicrobial resistance-and virulence-associated plasmids that spread among pathogens in food, animal, and clinical environments.
Data availability. This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers listed in Table 1 (BioProject number PRJNA312617). The SRA submission of FASTQ files has been recorded under the accession number PRJNA312617.
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